Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
2024年8月13日 - 7:55AM
ビジネスワイヤ(英語)
- Annual General Meeting elects new Board of Directors: Dr.
Frederick D. Sancilio, Dr. Harry Jacobson and Mr. Wesley
Ramjeet
- Board announces resignations of CEO Philip Young and COO Baxter
Phillips III
- The Board of Directors appoints Dr. Frederick D. Sancilio as
Chairman and CEO of the company
- Mr. Rick Goulburn appointed to the Board as its fourth
member
- Mr. Jeremy Wright joins the company as Board Advisor
Lobe Sciences Ltd ("Lobe Sciences" or the "Company") (CSE:
LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on
developing products to treat diseases with unmet medical needs,
today announced that a new board of directors (“Board”) has been
elected at the Company’s annual general meeting, with shareholders
electing the three previously announced nominees: Dr. Frederick D.
Sancilio, Dr. Harry Jacobson and Mr. Wesley Ramjeet. Lobe Sciences
also announces that Mr. Philip Young and Mr. Baxter Phillips have
elected to leave the Company to pursue other opportunities. The
Board has appointed Dr. Sancilio as Chairman of the Board and Chief
Executive Officer of the Company.
Dr. Sancilio, Chairman and CEO said, “While I regret the
departure of Mr. Young and Mr. Phillips, I am excited about the
opportunity to implement plans focused on creating shareholder
value while serving the needs of patients with serious unmet
medical needs.”
The Company also announces the appointment by the Board of Mr.
Rick Goulburn as its fourth member. Mr. Goulburn is expected to
take on a leadership role as the Company moves forward toward its
strategic goals. Finally, Lobe Sciences announces the appointment
of Mr. Jeremy Wright as a Board and Executive Advisor. Mr. Wright
will provide guidance to the Company and its Board concerning
strategic and administrative issues.
About Lobe Sciences Ltd.
Lobe Sciences is a biopharmaceutical company focused on
developing medicines to treat diseases with unmet medical needs.
The Company, through collaboration with industry-leading partners,
is engaged in novel research and development focused on treating
chronic cluster headache (an orphan disease), refractive anxiety,
opioid addiction and sickle cell disease. The Company is engaged in
Phase 1 and Phase 2 activities in its drug portfolio, and intends
to initiate the launch of Altemia®, a medical food designed to meet
the needs of sickle cell patients globally.
www.lobesciences.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ACCURACY OR ADEQUACY OF THIS RELEASE.
Cautionary Statement Regarding
"Forward-Looking" Information
This news release includes certain statements and information
that may constitute forward-looking information within the meaning
of applicable Canadian securities laws. All statements in this news
release, other than statements of historical facts, including
statements regarding future estimates, plans, objectives, timing,
assumptions or expectations of future performance, including,
without limitation: the Company’s intention to implement plans
focused on creating shareholder value while serving the needs of
patients with serious unmet medical needs; the anticipated focus of
the Company’s research and development activities; and the
anticipated launch of Altemia® are forward-looking statements and
contain forward-looking information. Generally, forward-looking
statements and information can be identified by the use of
forward-looking terminology such as “intends” or “anticipates”, or
variations of such words and phrases or statements that certain
actions, events or results “may”, “could”, “should” or “would” or
occur.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including, among other things, that: the Company’s planned
activities will be able to create shareholder value and address
serious unmet medical needs; the Company will continue to pursue
its planned research and development activities; and the Company
will launch Altemia®. These forward-looking statements are subject
to known and unknown risks, uncertainties and other factors that
may cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information. Important risks that may cause actual
results to vary, include, without limitation, the risk that: the
Company’s planned activities will be unable to create shareholder
value or address the targeted unmet medical needs; the Company is
unable to obtain the desired results from its current research and
development activities; and the Company is unable to launch
Altemia® or to do so on the timelines anticipated.
Although management of the Company has attempted to identify
important factors that could cause actual results to differ
materially from those contained in forward-looking statements or
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can
be no assurance that such statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements and
forward-looking information. Readers are cautioned that reliance on
such information may not be appropriate for other purposes. The
Company does not undertake to update any forward-looking statement,
forward-looking information or financial out-look that are
incorporated by reference herein, except in accordance with
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240812177123/en/
For further information: Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd. Investor and Media
Info@Lobesciences.com